Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 18/20 | 0.60 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049569 | 0.88 | GAA (0.59) | KLKB1DGAT1GAA | |
| SCHEMBL3355699 | 0.87 | GAA (0.54) | KLKB1DGAT1GAA | |
| SCHEMBL2361709 | 0.87 | GAA (0.54) | KLKB1DGAT1GAA | |
| SCHEMBL20521837 | 0.86 | GAA (0.53) | KLKB1DGAT1GAA | |
| SCHEMBL3356363 | 0.84 | GAA (0.51) | KLKB1DGAT1GAA | |
| SCHEMBL1049941 | 0.83 | GAA (0.56) | KLKB1DGAT1GAA | |
| SCHEMBL1048741 | 0.81 | KLKB1 (0.48) | KLKB1DGAT1GAA | |
| SCHEMBL14150628 | 0.81 | KLKB1 (0.48) | KLKB1DGAT1GAA | |
| SCHEMBL19253528 | 0.79 | HPGD (0.50) | KLKB1DGAT1 | |
| SCHEMBL21420053 | 0.76 | HSP90AA1 (0.43) | KLKB1DGAT1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | KLKB1 1387/4885DGAT1 137/4885GAA 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.